spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hyperkalemia 

 HSMN NewsFeed - 30 Dec 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 26 Mar 2024
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS(R)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 29 Dec 2022
FDA Grants Appeal for Ardelyx's XPHOZAH(R) (tenapanor)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 4 Apr 2022
Ardelyx Announces US Launch of IBSRELA(R), a New First-in-Class Treatment for IBS-C in Adults
Biopharmaceuticals Gastroenterology Product Launch
 HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 May 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2019
AliveCor Appoints Dr. Jacqueline Shreibati, Chief Medical Officer
Devices Cardiology Personnel
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 13 Sep 2018
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 6 Sep 2018
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to product/label mix-up
Biopharmaceuticals FDA Product Recall
 HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 19 Mar 2018
Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 12 Feb 2018
Ardelyx Announces Departure of Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology
 HSMN NewsFeed - 21 Nov 2017
Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 May 2017
Churchill Pharmaceuticals Expands Commercial Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 May 2017
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Oct 2016
Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 15 Jul 2016
Ardelyx to Raise $110 Million in a Private Placement
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Feb 2016
VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 4 Jan 2016
Ardelyx Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 23 Oct 2015
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX(TM) - First Low Dose SoluMatrix(R) Meloxicam for Osteoarthritis Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2015
ZS Pharma Names Jeffrey Farrow as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2015
Ardelyx to Raise $77.8 Million in a Private Placement and Announces New Product Candidate for the Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Jun 2015
Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds
Biopharmaceuticals Gastroenterology Acquisitions
 HSMN NewsFeed - 19 Feb 2015
ZS Pharma Hires Key Medical Affairs and Commercial Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2013
ZS Pharma Appoints Cynthia Smith as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2013
Relypsa Adds Renal Industry Veteran John P. Butler to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2011
Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 Million
Biopharmaceuticals Cardiology Venture Capital Personnel
 HSMN NewsFeed - 13 Sep 2010
Relypsa Raises $70 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2010
Relypsa Appoints Claire J. Lockey Vice President, Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2009
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2009
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2008
Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 19 Nov 2007
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 29 Oct 2007
Relypsa Formed With $33 Million Series A Funding to Discover and Develop Polymeric Drugs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 May 2007
Bayer HealthCare and Intendis Announce Strategic Alliance to Co-Promote Yaz(R) (Drospirenone/Ethinyl Estradiol) for Treatment of Moderate Acne
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 29 Jan 2007
FDA Approves New Indication for YAZ(R) to Treat Acne
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 9 Nov 2006
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
FDA Approves New Indication for YAZ(R) to Treat Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder (PMDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 May 2006
Combined Use of ATACAND(R) (candesartan cilexetil) and ACE Inhibitor Improves Heart Failure Outcomes More Than ACE Inhibitor Alone
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
hyperkalemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.